| SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats P Sa-Nguanmoo, P Tanajak, S Kerdphoo, T Jaiwongkam, ... Toxicology and applied pharmacology 333, 43-50, 2017 | 240 | 2017 |
| Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury P Tanajak, P Sa-Nguanmoo, S Sivasinprasasn, S Thummasorn, ... Journal of Endocrinology 236 (2), 69-84, 2018 | 127 | 2018 |
| FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats P Sa-Nguanmoo, P Tanajak, S Kerdphoo, P Satjaritanun, X Wang, ... Hormones and behavior 85, 86-95, 2016 | 117 | 2016 |
| Chronic treatment with prebiotics, probiotics and synbiotics attenuated cardiac dysfunction by improving cardiac mitochondrial dysfunction in male obese insulin-resistant rats W Tunapong, N Apaijai, S Yasom, P Tanajak, K Wanchai, T Chunchai, ... European journal of nutrition 57, 2091-2104, 2018 | 101 | 2018 |
| Vagus nerve stimulation exerts cardioprotection against myocardial ischemia/reperfusion injury predominantly through its efferent vagal fibers W Nuntaphum, W Pongkan, S Wongjaikam, S Thummasorn, P Tanajak, ... Basic research in cardiology 113, 1-20, 2018 | 91 | 2018 |
| Effects of fibroblast growth factor 21 on the heart P Tanajak, SC Chattipakorn, N Chattipakorn J Endocrinol 227 (2), R13-30, 2015 | 69 | 2015 |
| Fibroblast growth factor 21 (FGF 21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF 21 sensitivity, cardiac mitochondrial redox … P Tanajak, P Sa‐Nguanmoo, X Wang, G Liang, X Li, C Jiang, ... Acta Physiologica 217 (4), 287-299, 2016 | 48 | 2016 |
| FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats P Sa-Nguanmoo, P Tanajak, S Kerdphoo, T Jaiwongkam, X Wang, ... Biomedicine & Pharmacotherapy 97, 1663-1672, 2018 | 46 | 2018 |
| Increased plasma FGF21 level as an early biomarker for insulin resistance and metabolic disturbance in obese insulin-resistant rats P Tanajak, W Pongkan, SC Chattipakorn, N Chattipakorn Diabetes and vascular disease research 15 (3), 263-269, 2018 | 32 | 2018 |
| DPP-4 inhibitor and estrogen share similar efficacy against cardiac ischemic-reperfusion injury in obese-insulin resistant and estrogen-deprived female rats S Sivasinprasasn, P Tanajak, W Pongkan, W Pratchayasakul, ... Scientific reports 7 (1), 44306, 2017 | 24 | 2017 |
| Energy restriction combined with dipeptidyl peptidase-4 inhibitor exerts neuroprotection in obese male rats H Pintana, P Tanajak, W Pratchayasakul, P Sa-Nguanmoo, T Chunchai, ... British Journal of Nutrition 116 (10), 1700-1708, 2016 | 24 | 2016 |
| Dipeptidyl peptidase-4 inhibitor, vildagliptin, improves trabecular bone mineral density and microstructure in obese, insulin-resistant, pre-diabetic rats N Charoenphandhu, P Suntornsaratoon, P Sa-Nguanmoo, P Tanajak, ... Canadian journal of diabetes 42 (5), 545-552, 2018 | 21 | 2018 |
| parameters, characteristics, and criteria for defining the term “FGF21 resistance” P Tanajak Endocrinology 158 (5), 1523-1524, 2017 | 20 | 2017 |
| Impaired mitochondria and intracellular calcium transients in the salivary glands of obese rats J Ittichaicharoen, N Apaijai, P Tanajak, P Sa-Nguanmoo, N Chattipakorn, ... Applied Physiology, Nutrition, and Metabolism 42 (4), 420-429, 2017 | 20 | 2017 |
| Toll-like receptor 4 inflammatory perspective on doxorubicin-induced cardiotoxicity N Sumneang, P Tanajak, TT Oo Molecules 28 (11), 4294, 2023 | 19 | 2023 |
| Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats P Tanajak, H Pintana, N Siri-Angkul, J Khamseekaew, N Apaijai, ... J Endocrinol 232 (2), 189-204, 2017 | 16 | 2017 |
| Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance J Ittichaicharoen, N Apaijai, P Tanajak, P Sa-Nguanmoo, N Chattipakorn, ... Archives of Oral Biology 85, 148-153, 2018 | 11 | 2018 |
| Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase‐4 inhibitor in prediabetic rats P Tanajak, P Sa‐nguanmoo, N Apaijai, X Wang, G Liang, X Li, C Jiang, ... Cardiovascular therapeutics 35 (4), e12263, 2017 | 10 | 2017 |
| FGF21 therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homeostasis and structural changes … P Tanajak, P Sa-Nguanmoo, X Wang, G Liang, X Li, C Jiang, ... Acta Physiol.(Oxf.) 10, 2016 | 3 | 2016 |
| Navigating the complex landscape of cardiac metabolism in health and disease states P Tanajak, T Pasachan INNOSC Theranostics and Pharmacological Sciences 7 (2), 2302, 2024 | | 2024 |
